Publications
Knowledge generated at IrsiCaixa is shared with the scientific community through the publication of articles in high impact scientific journals.
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
[Resistance profile and genetic barrier of dolutegravir].
Primary resistance to integrase strand-transfer inhibitors in Europe.
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Determinants of virological failure and antiretroviral drug resistance in Mozambique.
Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients.
Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death.
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables.
Characterization of the influence of mediator complex in HIV-1 transcription.